Browse studies

Find your next paid study

127 recruiting studies matching your filters

A Phase 1a/1b, First-in-Human, Open-Label, Multi-Center, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LB-LR1109, When Administered Alone for the Treatment of Advanced or Metastatic Solid Tumors, and in Combination With Atezolizumab for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(…

Non-small Cell Lung Cancer(NSCLC)Head and Neck Squamous Cell Carcinoma(HNSCC)Renal Cell Carcinoma(RCC)+2 more

A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy in Patients With Locally Advanced or Metastatic Cancers Following One or More Prior Therapies

This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. r…

Advanced CancerAdvanced Solid TumorMelanoma+15 more

Estimated

~$10 – $8,750

7 Hills Pharma, LLCNCT06362369

Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer

This is a correlative (lab-based) study aiming to identify protein markers in urine extracellular vesicles (EVs) that can be used to develop non-invasive molec…

Renal Cell CarcinomaClear-cell Renal Cell CarcinomaPapillary Renal Cell Carcinoma+2 more

Estimated

~$10 – $750

Mayo ClinicNCT07243067

Phase 1

A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed…

Solid Tumor, AdultMicrosatellite Stable Colorectal CancerHead and Neck Squamous Cell Carcinoma+10 more

Estimated

~$10 – $8,750

KaliVir ImmunotherapeuticsNCT06444815

Phase 2

A Phase 2 Study of RP2 With Tivozanib in Patients With Metastatic Renal Carcinoma After Progression to Immunotherapy

This phase II trial tests the effect of RP2 and tivozanib in treating patients with renal cell cancer that has spread from where it first started (primary site…

Advanced Clear Cell Renal Cell CarcinomaAdvanced Renal Cell CarcinomaAdvanced Sarcomatoid Renal Cell Carcinoma+6 more

Estimated

~$10 – $6,250

City of Hope Medical CenterNCT07218692

Phase 2

Phase 2, Open-label, Single Cohort, Multicenter Trial for Sequential Treatment of High Dose Cabozantinib on/After Progression on Cabozantinib Monotherapy in Advanced Renal Cell Carcinoma (Seq-Cabo)

The goal of this clinical trial is to learn about the effects of a higher dose of ncabozantinib in patients with advanced renal cell carcinoma who have progres…

RCCRenal Cell Carcinoma

Estimated

~$10 – $6,250

University of Texas Southwestern Medical CenterNCT05931393

Phase 1

An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-102, a CD80-IgG4 Fc-IL-2v Bispecific Fusion Protein, As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced or Metastatic Solid Tumors (KEYNOTE-G08)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination wi…

Advanced Solid TumorMetastatic Solid TumorSoft Tissue Sarcoma (STS)+6 more

Estimated

~$10 – $8,750

GI Innovation, Inc.NCT05824975